In the pharmaceutical industry, the development of new products involves several challenges. Here is a note on the challenges: 1.      Idea generation : The first challenge is to determine whether an idea is worth considering. This involves evaluating whether the idea aligns with the company’s objectives and if it requires modifications to the existing product or marketing program. 2.      Idea screening : The second challenge is to screen the product idea to ensure it is compatible with the company’s objectives, strategies, and resources. This step helps filter out ideas that may not be feasible or aligned with the company’s goals. 3.      Concept development and testing : The third challenge is to develop and test a concept that consumers would be willing to try. This involves creating a concept that resonates with the target audience and conducting tests to gather feedback and validate its potential. 4.      Marketing strategy development : The fourth challenge is to d

Companies that fail to develop new products are putting themselves at great risk. Their existing products are vulnerable to changing customer needs and tastes, new technologies, shortened product life cycles, and increased domestic and foreign competition. New technologies are especially threatening. Most established companies focus on incremental innovation. Newer companies create disruptive technologies that are cheaper and more likely to alter the competitive space. Established companies are slow to react or invest in these disruptive technologies because they threaten their investment. Then they suddenly find themselves facing formidable new competitors, and many fail. At the same time, new product development is risky. Several factors tend to hinder new-product development: 1.        Shortage of important ideas in certain areas:  There may be a few ways left to improve some basic products (such as steel, and detergents). 2.        Fragmented markets:  Companies have to aim their

Azithromycin Azithromycin was first approved for human use in 1988 by the Croatian pharmaceutical company Pliva 1 . According to the World Health Organization (WHO), there is a growing concern about the increasing resistance of bacteria to antibiotics, including azithromycin. The WHO report reveals high levels of resistance in bacteria causing life-threatening bloodstream infections, as well as increasing resistance to treatment in several bacteria causing common infections in the community based on data reported by 87 countries in 2020 2 . However, the report does not mention the specific organism responsible for resistance to azithromycin. Erythromycin  Erythromycin was first isolated in 1952 from the bacteria Saccharopolyspora erythraea 1 . According to the Centers for Disease Control and Prevention (CDC), the percentage of invasive Group A Streptococcus (GAS) infections that are resistant to erythromycin has nearly tripled in 8 years 2 . However, the CDC does not mention the spec